IBRX261120P00010000
IBRX Nov 20 2026 10.00 Put
optionOPRA
EODOct 16, 2026
1.48USD+28.696%(+0.33)99Vol735OI
Loading…
Underlying
Underlying Price
$8.48
Type
Put
Strike
10
Expiration
Nov 20, 2026
DTE
31d
Moneyness
ITM
Intrinsic
$1.52
IBRX 10 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.93 | +78.85% | 176 | 1,656 |
| Oct 30, 2026 | 10d | $1.15 | +76.92% | 2 | 259 |
| Nov 6, 2026 | 17d | $1.47 | +14.84% | 2 | 125 |
| Nov 13, 2026 | 24d | $1.05 | -12.50% | 4 | 11 |
| Nov 20, 2026 | 31d | $1.48 | +28.70% | 99 | 735 |
| Nov 27, 2026 | 38d | $1.52 | -12.14% | 1 | 1 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $2.06 | +1.48% | 50 | 6,506 |
| Mar 19, 2027 | 150d | $2.40 | -4.00% | 10 | 68 |
| Apr 16, 2027 | 178d | $4.80 | +0.00% | 10 | 10 |
| May 21, 2027 | 213d | $3.00 | -36.17% | 10 | 164 |
| Aug 20, 2027 | 304d | $4.70 | +0.00% | 1 | 16 |
| Nov 19, 2027 | 395d | $2.50 | +0.00% | 1 | 1 |
| Jan 21, 2028 | 458d | $3.50 | +3.24% | 50 | 3,806 |
| Mar 17, 2028 | 514d | $4.00 | -6.32% | 1 | 20 |
| Jan 19, 2029 | 822d | $4.45 | +7.23% | 1 | 89 |
IBRX Nearby Strikes · Nov 20, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 4 P | $0.03 | -40.00% | 1 | 6 | OTM |
| 5 P | $0.10 | +0.00% | 1 | 256 | OTM |
| 6 P | $0.10 | -23.08% | 250 | 2,963 | OTM |
| 7 P | $0.25 | +66.67% | 1,067 | 3,286 | OTM |
| 8 P | $0.55 | +30.95% | 264 | 1,909 | OTM |
| 9 P | $0.90 | +21.62% | 65 | 1,550 | ITM |
| 10 P | $1.48 | +28.70% | 99 | 735 | ITM |
| 11 P | $2.20 | +41.03% | 7 | 394 | ITM |
| 12 P | $2.20 | -26.67% | 20 | 74 | ITM |
| 13 P | $3.60 | +16.88% | 2 | 3 | ITM |
| 14 P | — | — | 0 | 0 | ITM |
| 15 P | — | — | 0 | 0 | ITM |
| 16 P | — | — | 0 | 0 | ITM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.